Skip to main content
. Author manuscript; available in PMC: 2018 Oct 9.
Published in final edited form as: Pharmacol Res. 2017 Dec 2;129:365–374. doi: 10.1016/j.phrs.2017.11.033

Figure 2: Natural products targeting important pathways in retinoblastoma.

Figure 2:

Retinoblastoma is characterized by the lack of pRB or the overexpression of MYCN. (A) BET inhibitors target MYCN (blue). (B) Wortmannin, β-lapachone, and paclitaxel target ARF/MDM2-MDMX/p53 (pink). (C) Trichostatin and topotecan target HIF-1 (purple). (D) Celastrol and chebulagic acid target NFκB pathway (green).